Last reviewed · How we verify
Granisetron (Group G)
Granisetron is a selective serotonin 5-HT3 receptor antagonist that blocks nausea and vomiting signals in the chemoreceptor trigger zone and gastrointestinal tract.
Granisetron is a selective serotonin 5-HT3 receptor antagonist that blocks nausea and vomiting signals in the chemoreceptor trigger zone and gastrointestinal tract. Used for Chemotherapy-induced nausea and vomiting (CINV), Postoperative nausea and vomiting (PONV), Radiation-induced nausea and vomiting.
At a glance
| Generic name | Granisetron (Group G) |
|---|---|
| Also known as | antiemetic |
| Sponsor | University of Malaya |
| Drug class | 5-HT3 receptor antagonist |
| Target | 5-HT3 receptor |
| Modality | Small molecule |
| Therapeutic area | Oncology, Gastroenterology |
| Phase | FDA-approved |
Mechanism of action
Granisetron works by competitively blocking 5-HT3 receptors on vagal afferent nerves in the gastrointestinal tract and in the chemoreceptor trigger zone of the brain. By preventing serotonin from binding to these receptors, it suppresses the signals that trigger the vomiting reflex, making it highly effective for chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea and vomiting (PONV).
Approved indications
- Chemotherapy-induced nausea and vomiting (CINV)
- Postoperative nausea and vomiting (PONV)
- Radiation-induced nausea and vomiting
Common side effects
- Headache
- Constipation
- Asthenia/fatigue
- Diarrhea
- Abdominal pain
Key clinical trials
- A Comparison Between Palonosetron Versus Granisetron as PONV Prophylaxis in Scoliotic Patients Undergoing Spine Surgery (PHASE4)
- Clonidine Versus Granisetron for Shivering Prevension (PHASE2)
- Role of Granisetron in Preventing Hypotension After Spinal Anesthesia With Levobupivacaine in Rheumatic Patients Undergoing Elective Cesarean Section (PHASE2, PHASE3)
- Analgesia Management in Bariatric Surgery (NA)
- Granisteron Versus Metoclopramide in Laparoscopic Cholecystectomy (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Granisetron (Group G) CI brief — competitive landscape report
- Granisetron (Group G) updates RSS · CI watch RSS
- University of Malaya portfolio CI